GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

The FTSE 250 business's stock jumped 4.7%, or 6.3p, to 141.8p as investors bet it could be next food delivery group to be ...

GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated ...

Two former FTSE 100 stocks were in the spotlight today after Just Eat Takeaway.com backed a £3.4 billion takeover and B&M ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.

GSK’s share price has fallen a long way on a combination of factors, but do its recent strong results leave its current price ...

Blueprint Medicines Corporation, a Delaware-based biopharmaceutical company, recently released its financial results for the year ended December 31, 2024, along with key business highlights. The ...

Q4 2024 Earnings Call Transcript February 13, 2025 Blueprint Medicines Corporation misses on earnings expectations. Reported ...

Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT ...